Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
110 participants
OBSERVATIONAL
2025-08-25
2028-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Markers of Bone Turnover in Saliva and How This Compares to Urine and Blood
NCT00323336
Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density
NCT01250314
Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability
NCT05721898
Evaluation of the Effects of Covid 19 Infection on Bone Remodeling and Bone Fragility
NCT05352295
Osteogenic Profiling of Normal Calvarial Bone
NCT02933359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
New Traumatic Fractures
Anyone age 18 or over presenting to participating sites for care of new, traumatic appendicular fractures.
Blood draws to assess RNA expression levels
None. Standard of Care (SOC) only.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood draws to assess RNA expression levels
None. Standard of Care (SOC) only.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provision of informed consent for study participation for self in the English language as indicated by a signed and dated, current, and IRB-approved Informed Consent Form (ICF) from
1. patients making their own SOC clinical decisions prior to the time of the 1st blood sample collection, or
2. persons initially unable to make their own SOC clinical decisions, who regain capacity to make clinical care decisions after study blood sample collection during the enrollment window and/or before hospital discharge.
2. Patient is expected to receive follow-up SOC fracture care at the Site.
3. Either biological sex at birth (i.e., male or female).
4. Any self-determined gender or sexual preference.
5. Any race and/or ethnicity combination.
6. Age 18 years or older at the time of enrollment; no maximum age.
7. Body weight estimated to be or measured at ≥110 lbs.
8. Presentation for care within 7 calendar days of injury for at least one new traumatic fracture of any bone in the appendicular skeleton with or without additional fractures of the appendicular or axial skeleton and with or without any other traumatic injuries.
1. A qualifying fracture:
* May be open or closed as locally defined per SOC.
* May be displaced or non-displaced per SOC.
* Must result from blunt or penetrating trauma.
* May not be in a location of the body that was chronically paralyzed pre-trauma or has become permanently paralyzed because of the trauma.
* Does not include traumatic amputation above the fracture Site for qualifying fractures
2. Index treatment plan:
* May be operative or non-operative.
* May include staged treatment with or without the use of external fixators, and/or antibiotic beads, and/or other planned intervention.
* Does not include hemi- or total arthroplasty to treat the qualifying fracture.
* Does not include amputation above the qualifying fracture.
9. In good general health as evidenced by clinical presentation and/or medical history and without any diagnoses that preclude a life expectancy of at least 2 years after injury.
10. No healed or unhealed fractures within 12 months prior to the event resulting in the qualifying fracture.
11. Blood collection through venipuncture at the volume and frequency per protocol is not contraindicated either through past medical history or current clinical status
12. 45 CFR 46 Subpart B: For females of reproductive potential: not pregnant at the time of study enrollment.
13. CFR 46 Subpart C: Does not meet the CFR definition of Prisoner.
14. Other vulnerable populations:
1. Not an individual with pre-existing or newly acquired permanently impaired decision-making capacity , and/or
2. Not an individual who would be considered an economically or educationally disadvantaged person prior to the qualifying injury as determined by the Site study team per Site standards.
\-
Exclusion Criteria
1. Enrolled in another research study that requires any study-specific blood draws from 0 - ≤84 Days post-injury or a study that prohibits co-enrollment of any kind.
2. Traumatic injuries at presentation are limited to soft tissue injuries and/or axial skeletal fractures.
3. The presentation appendicular fractures is a result of pathological not traumatic mechanism
4. Any other circumstances that in the opinion of the PI would either put the successful completion of the study at risk, and/or which makes study participation unduly burdensome to the Subject.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharPoint Research, Inc.
INDUSTRY
Children's Hospital of Philadelphia
OTHER
Cooperative Human Tissue Network - Eastern Division (CHTN-ED)
UNKNOWN
Osetomics, LLC
UNKNOWN
Resonant Clinical/Therapak, Claremont, California
UNKNOWN
ResearchDx, Irvine, CA
UNKNOWN
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samir Mehta, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Annamarie D Horan, MPA, PhD
Role: STUDY_DIRECTOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Davis Medical Center
Sacramento, California, United States
Indiana University
Bloomington, Indiana, United States
University of Missouri
Columbia, Missouri, United States
Wake Forest University Health Sciences/Advocate Health
Charlotte, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
University of Texas Health Science Center at Houston
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
855303
Identifier Type: -
Identifier Source: org_study_id
UPCC-02924
Identifier Type: OTHER
Identifier Source: secondary_id
50526
Identifier Type: OTHER
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.